TechCrunch : OpenMind wants to be the Android operating system of humanoid robot

OpenMind wants to be the Android operating system of humanoid robots

Many companies are focused on building robots, or the hardware components to help them move, grip objects, or interact with the world around them. OpenMind is focused under the hood.

The Silicon Valley-based startup is building a software layer, called OM1, for humanoid robots that acts as an operating system. The company compares itself to being the Android for robotics because its software is open and hardware agnostic.

Stanford professor Jan Liphardt, the founder of OpenMind, told TechCrunch that humanoids and other robots have been around and able to do repetitive tasks for decades. But now that humanoids are being developed for use cases that require more human-to-machine interactions, like having a humanoid in your home, they need a new operating system that thinks more like a human.

“All of a sudden, this world is opening where machines are able to interact with humans in ways I’ve certainly never before seen,” Liphardt said. “We’re very much believers here that it’s not just about the humans, but we really think of ourselves as a company that is a collaboration between machines and humans.”

OpenMind unveiled on Monday a new protocol called FABRIC that allows robots to verify identity and share context and information with other robots.

Unlike humans, machines can learn almost instantly, Liphardt said, which means giving them a better way to connect to other robots will allow them to more easily train and absorb new information.

Liphardt gave the example of languages and how robots could connect to each other and share data on how to speak different languages, which would help them better interact with more people without having to be taught each language by a human directly.

“Humans take it for granted that they can interact with any other human on Earth,” Liphardt said. “Humans have built a lot of infrastructure around us that allows us to trust other people, call them, text them and interact and coordinate and do things together. Machines, of course, are going to be no different.”

OpenMind was founded in 2024 and is gearing up to ship its first fleet of 10 OM1-powered robotic dogs by September. Liphardt said that he’s a big believer in getting the tech out there and iterating on it after the fact.

“We full well expect all the humans that will be hosting these quadrupeds, they’ll come back with a long list of things they didn’t like or they want, and then it’s up to us to very, very quickly iterate and improve the machines,” he said.

The company recently raised a $20 million funding round led by Pantera Capital with participation from Ribbit, Coinbase Ventures, and Pebblebed, among other strategic investors and angel investors.

Now, the company is focused on getting its tech into people’s homes and starting to iterate on the product.

“The most important thing for us is to get robots out there and to get feedback,” Liphardt said. “Our goal as a company is to do as many of these tests as we can, so that we can very rapidly identify the most interesting opportunities where the capabilities of the robots today are optimally matched against what humans are looking for.”

FT : UK aims to slash clinical trials set-up time from 9 months to 10 weeks

UK aims to slash clinical trials set-up time from 9 months to 10 weeks
New system would avoid ‘unnecessary contracts’ and ‘duplication on technical assurances’

The UK government is seeking to cut the time it takes to set up clinical trials by more than two-thirds, as it aims to lure more companies to Britain and boost the life sciences sector.

A pilot programme reduced set-up times for an mRNA norovirus vaccine trial from almost nine months to just 70 days, according to figures seen by the Financial Times. 

It currently takes an average of 250 days to launch a trial within the NHS, which ministers have said they want to reduce to “150 days or less” by March next year.

But the new process, if rolled out, could see that streamlined to just 10 weeks.

The Vaccine Innovation Pathway (VIP) trial was backed by public funding and is now being cited by ministers as a model for streamlining the process.

A new contracting system would allow researchers and pharmaceutical companies to avoid “unnecessary contracts” and “duplication on technical assurances,” allowing them to accelerate trial launches.

Officials said this new standardised commercial contracting process removed unnecessary negotiations and duplicative steps at sites.

Contract templates and agreements are looked at per study, and accepted by participating sites without any modification, rather than the current system that often requires new contracts for each stage or testing site.

This will “free up workforce capacity and drive efficiencies,” the officials said.

Ministers have targeted life sciences as one of the eight “growth” sectors in their industrial strategy, and hope the NHS can be a strong lure for pharmaceutical companies around the world to set up trials.

Health minister Karin Smyth said: “For too long, some of the country’s greatest scientists have been trapped in a tangled web of bureaucracy — tied up by endless contracts and pointless paperwork — with new treatments delayed and patients missing out.  

“We’re transforming the UK into a hotbed for innovation — ensuring the most innovative companies can get their products on the market and to the NHS frontline as quickly as possible.”

Under the government’s ten-year plan for the health service announced earlier this year, millions of patients will be granted direct access to clinical trials under the expansion of the NHS app. 

But the industry has previously criticised the UK for paying far less than many peer countries for products and warned that a recent rise in the UK’s medicine sales tax left the country uninvestable.

Professor Lucy Chappell, chief scientific adviser to the department, said: “We’re taking a series of steps to strengthen the sector — streamlining the set-up and delivery of clinical trials, unlocking the power of our impressive life sciences sector and harnessing our world leading science for patients across the country.”

She added: “Research is a core part of care, driving better patient outcomes, supporting our workforce, and ensuring that our health and care system innovates today and is fit for the future.”

>>> US Research Calls I

Research Calls I
  • Upgrades
    • Affiliated Managers (AMG) upgraded to Buy from Hold at TD Cowen, tgt $255
    • Aimco (AIV) upgraded to Outperform from Peer Perform at Wolfe Research, tgt $10
    • Air France-KLM (AFLYY) upgraded to Equal Weight from Underweight at Barclays
    • Alamo Group (ALG) upgraded to Outperform from Neutral at Robert W. Baird, tgt $260
    • Alnylam (ALNY) upgraded to Outperform from Perform at Oppenheimer, tgt $490
    • Alnylam (ALNY) upgraded to Peer Perform from Underperform at Wolfe Research, tgt $368
    • BJ's Restaurants (BJRI) upgraded to Buy from Hold at The Benchmark Company , tgt $44
    • Deutsche Lufthansa (DLAKY) upgraded to Equal Weight from Underweight at Barclays
    • Federated Hermes (FHI) upgraded to Neutral from Underweight at JPMorgan, tgt $54
    • Fortrea (FTRE) upgraded to Outperform from Neutral at Robert W. Baird, tgt $9
    • IAG (ICAGY) upgraded to Equal Weight from Underweight at Barclays
    • Kimberly-Clark (KMB) upgraded to Neutral from Underweight at JPMorgan, tgt $138
    • Lloyds Banking (LYG) upgraded to Outperform from Sector Perform at RBC Capital
    • MasTec (MTZ) upgraded to Outperform from Neutral at Robert W. Baird, tgt $210
    • Spotify (SPOT) upgraded to Neutral from Reduce at Phillip Securities, tgt $600
    • Zevia (ZVIA) upgraded to Outperform from Market Perform at Telsey Advisory Group, tgt $5
  • Downgrades
    • AvalonBay (AVB) downgraded to Neutral from Overweight at Piper Sandler, tgt $200
    • Baxter (BAX) downgraded to Hold from Buy at Stifel, tgt $25
    • Coinbase (COIN) downgraded to Sell from Neutral at Compass Point, tgt $248
    • EPR Properties (EPR) downgraded to Sector Perform from Outperform at RBC Capital, tgt $58
    • Essex Property Trust (ESS) downgraded to Neutral from Overweight at Piper Sandler, tgt $275
    • Shell (SHEL) downgraded to Hold from Buy at HSBC
    • Tronox (TROX) downgraded to Neutral from Buy at UBS, tgt $3.60
    • Vera Therapeutics (VERA) downgraded to Peer Perform from Outperform at Wolfe Research
  • Others
    • AeroVironment (AVAV) initiated with an Outperform at Citizens JMP, tgt $325
    • Akero Therapeutics (AKRO) initiated with a Buy at TD Cowen, tgt $76
    • Chevron (CVX) resumed with an Overweight at Morgan Stanley, tgt $174
    • Kinross Gold (KGC) initiated with a Buy at UBS, tgt $20
    • Liberty Formula One (FWONK) initiated with a Neutral at BofA Securities, tgt $110
    • Mind Medicine (MNMD) resumed with an Outperform at Oppenheimer, tgt $25
    • Philip Morris (PM) initiated with an Outperform at KGI Securities, tgt $188
    • Pony AI (PONY) initiated with a Buy at UBS, tgt $20
    • Wave Life Sciences (WVE) initiated with a Buy at Canaccord, tgt $19
    • WeRide (WRD) initiated with a Buy at UBS, tgt $12

>>> Ralph Lauren target raised to $335 at Telsey Advisory Group (293.77)

Ralph Lauren target raised to $335 at Telsey Advisory Group (293.77)
Telsey Advisory Group raises their RL tgt to $335 from $315. Analyst Dana Telsey noted, "RL enters FY26 with sustained operating momentum, driven by disciplined execution of its brand elevation strategy, continued product innovation, and a diversified global footprint. Recent performance reinforces the view that RL is navigating macroeconomic headwinds with agility, supported by its multiyear track record of HSD AUR growth and a flexible, cost-efficient supply chain. Throughout FY24 and into FY25, RL has consistently delivered earnings beats across regions, demonstrating resilience in a volatile environment and reflecting the strength of RL's premium positioning and its appeal to a broader, younger, and increasingly global consumer base. The first quarter FY26 revenue guide, calling for high-single-digit growth in constant currency (issued in the face of an uncertain macro backdrop), signals continued confidence in the underlying demand for the brand. Moreover, RL's consistent ability to drive higher AURs while expanding its customer base (particularly among younger, female, and less price-sensitive demographics), suggests that recent investments in product, marketing, and channel mix are resonating with target consumers. With improving visibility into gross margin leverage and operating efficiency, RL appears poised to further reinvest in long-term brand health while delivering attractive shareholder returns. As such, we maintain our Outperform Rating, and, given expectations for continued strength in FY26, we raise our price target to $335, from $315 prior. Our increased price target assumes a 21.8x multiple on our two-year forward EPS estimate of $15.34, compared to the current NTM multiple of 20.7x."

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • BRKR -7.8%, KOS -3.1%, CNA -2%, MUFG -1.5%, BRK.B -0.7%
Other news:
  • MVST -5% (CFO Carl (Pat) Schultz steps down)
  • YMM -4.1% (announces changes to its freight brokerage service)
  • SUNS -2.3% (files for $500 mln mixed securities shelf offering)
  • HLVX -2% (enters into a definitive agreement to be acquired by XOMA Royalty (XOMA) for $1.95 in cash per share plus a contingent value right)
  • ALTS -1.1% (files for $2 bln mixed securities shelf offering)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • COMM +42% (also entered into a definitive agreement to sell its Connectivity and Cable Solutions segment to Amphenol Corporation), ZEPP +19%, W +11%, ENR +8.4%, IDXX +6.4%, AXSM +6%, KRYS +5.1%, EEX +4.3%, TSEM +4.1%, FRPT +3.7%, BNTX +2.5%, BCRX +2.5%, SPNT +2%, L +1.9%, DJT +1.6%, WAT +1.6%,
Other news:
  • SCS +45.6% (HNI Corporation (HNI) to acquire Steelcase for total consideration of approximately $2.2 bln)
  • OPEN +14.2% (received written notice from the Nasdaq that the Company has regained compliance with Nasdaq's minimum bid price requirement)
  • TMC +11.8% (The Metals Company and Tonga announce updated sponsorship agreement for Tonga Offshore Mining; releases two economic studies with combined NPV of $23.6B and declares world-first nodule reserves)
  • ELME +9.1% (concludes strategic alternatives review process; to sell 19 properties, remaining assets to be marketed for sale)
  • CERT +9% (announces the EMA has formally qualified the Simcyp Simulator for use in regulatory submissions across the EU)
  • KGS +7.2% (to join S&P SmallCap 600)
  • FFAI +7% (Shares Weekly Investor Update)
  • SPOT +4% (announces upcoming changes to Spotify Premium subscriptions)
  • QBTS +3.7% (introduces new developer tools to advance quantum AI exploration and innovation)
  • SITC +3.5% (announces two sales and special common distribution)
  • UBS +2.7% (resolves legacy Credit Suisse matter with US Department of Justice)
  • PLTR +2.1% (awarded a US Army contract transitioning existing contracts in which Palantir is currently a prime or subcontractor to this $10 bln enterprise agreement)
  • TSLA +2.1% (discloses summary of the 2025 CEO Elon Musk interim award; produced EV sales fall 8% in July, according to Reuters)
  • LYG +2% (issues motor finance update)
  • ALGN +1.8% (CEO bought 7576 shares at $131.49 worth ~$996K)
  • AA +1.8% (explores feasibility of Gallium Critical Mineral Production in Western Australia)
  • HPK +1.8% (announces amendments to its term loan credit agreement and senior credit facility agreement)
  • TTEC +1% (provides update on potential take private transaction)

>>> Blade Air Mobility announces an agreement to sell Blade’s passenger division

Blade Air Mobility announces an agreement to sell Blade’s passenger division to Joby Aviation, Inc. (JOBY) for up to $125 mln (3.78)
  • Blade Passenger division to be sold to Joby Aviation for up to $125 mln.
  • Blade's Medical division will remain public and rebrand as Strata post-close, focusing entirely on its rapidly growing contractual medical services and logistics business.
  • Long-term partnership between Joby and Strata will provide future access to Joby eVTOLs for medical flights.
  • Divestiture is expected to be Adjusted EBITDA and Free Cash Flow neutral.